共 332 条
[1]
Sitohy B(2012)Anti-VEGF/VEGFR therapy for cancer: reassessing the target Cancer Res 72 1909-1914
[2]
Nagy JA(2014)A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 699-708
[3]
Dvorak HF(2010)Response assessment challenges in clinical trials of gliomas Curr Oncol Rep 12 68-75
[4]
Gilbert MR(2009)Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment Radiology 252 182-189
[5]
Dignam JJ(2017)Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials Clin Cancer Res 23 5745-5756
[6]
Armstrong TS(2014)Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab J Neuro-Oncol 119 149-158
[7]
Wefel JS(2020)Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial Neuro-Oncology 22 1667-1676
[8]
Blumenthal DT(2015)Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial Neuro-Oncology 17 1148-1156
[9]
Vogelbaum MA(2015)Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma Neuro-Oncology 17 1139-1147
[10]
Colman H(2016)MR perfusion-derived hemodynamic parametric response mapping of bevacizumab efficacy in recurrent glioblastoma Radiology 279 542-552